RTP Mobile Logo
Hodgkin Lymphoma Update, Issue 1, 2019
Released February 2019

Featuring interviews with Drs David J Straus and Radhakrishnan Ramchandren. (Audio Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin lymphoma (HL).

    In contrast to the more prevalent non-Hodgkin lymphomas, HL is a rare cancer that is relatively chemosensitive and often curable when treated appropriately. However, a proportion of affected patients either receive diagnosis at an advanced stage of disease or harbor unfavorable risk factors that are associated with a suboptimal response to primary combined-modality treatment (chemotherapy/involved-field radiation therapy) and/or a high probability of early relapse. Historically the therapeutic challenge posed by this HL population was significant as no new systemic agent had been approved in this setting for more than 3 decades. The introduction of brentuximab vedotin (BV) and the anti-PD-1 antibodies nivolumab and pembrolizumab has improved outcomes but has also added considerable complexity to current treatment decision-making. Similarly, extensive published and ongoing research attempting to better define and expand the role of these agents and other compounds leveraging diverse mechanisms of action further add to the realm of educational priorities related to this challenging disease.

    In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with the perspectives of leading clinical investigators, this CME program is designed to assist medical oncologists with the formulation of up-to-date clinical management strategies for the care of patients with HL.


    • Appraise the FDA approval of BV as a component of first-line therapy for patients with newly diagnosed classical HL, and assess the current and future impact on routine clinical practice.
    • Appreciate available Phase III data documenting the efficacy of BV as consolidation therapy after autologous stem cell transplant, and use this knowledge to identify patients appropriate for this therapeutic approach.
    • Develop a long-term care plan for individuals with relapsed/refractory HL, considering prior exposure to systemic therapy, eligibility for transplant, symptomatology, performance status and personal goals for treatment.
    • Compare and contrast the efficacy and safety of various approved immunotherapeutic approaches for HL to determine the current utility of each in clinical practice.
    • Recall the design of ongoing clinical trials evaluating approved therapies and novel investigational agents for the treatment of HL, and counsel appropriately selected patients about availability and participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    David J Straus, MD
    Attending Physician, Lymphoma Service
    Department of Medicine
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, DAVA Oncology, Elsevier, Juno Therapeutics, a Celgene Company, OncoTracker, Takeda Oncology; Speakers Bureau: Medical Crossfire, Roche China.

    Radhakrishnan Ramchandren, MD
    Professor, Hematology Oncology
    Division Chief
    University of Tennessee
    Knoxville, Tennessee

    Advisory Committee: Bristol-Myers Squibb Company, Genentech, Kite Pharma Inc; Contracted Research: Merck, Seattle Genetics.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Seattle Genetics.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: February 2019
    Expiration date: February 2020

Acknowledge and close

Listen to audio:
Hodgkin Lymphoma Update, Issue 1, 2019
Released February 2019

Featuring interviews with Drs David J Straus and Radhakrishnan Ramchandren. (Audio Program)

Read print: